THE SHORT ANSWER
High-Performance Science Teams™ helps life science product teams R&D, product management, QC, regulatory, operations, marketing, and technical support launch reagents, assay kits, and consumables on time and on spec. It targets the cross-functional behaviors behind spec creep, late lot-release criteria, and launches the commercial team isn’t ready to support.
How often do new life science products actually deliver?
Less often than roadmaps assume. In TechLink’s 2024 R&D Innovation Performance Study of R&D-driven companies, about three-quarters of respondents reported that half or fewer of their new product development projects result in sales, more than half said half or fewer hit projected sales targets, and about a quarter take more than a year to develop a new product. Meanwhile, 83% plan to increase their number of SKUs over the next three years.
The study spans industries life science is a minority of respondents so treat these as directional. But for a reagent or kit company adding SKUs every quarter, the implication is uncomfortable: more launches through the same cross-functional machinery means more of the same slippage.
Where do reagent and kit launches break down?
- Spec creep in R&D. The assay team keeps optimizing sensitivity or dynamic range after the product requirements were set, because no one has the authority or the protocol to freeze the design.
- Product managers with accountability but no authority. Product management owns the launch date but can’t make R&D, QC, or supply chain commit to theirs.
- Lot-release criteria set late. QC specifications and stability data arrive after design transfer, and lot-to-lot consistency complaints arrive after launch.
- Design controls treated as regulatory’s problem. For products moving from RUO toward IVD or ISO 13485 environments, documentation is back-filled instead of built into how the team works.
- Claims the data doesn’t yet support. Marketing launches on application notes and validation data that R&D considers preliminary.
- Technical support and FAS learn about the product at launch. The people customers call first are the last to be trained.
Why doesn’t a new stage-gate process or PLM system fix it?
When launches slip, tools companies reach for vertical fixes: a formal stage-gate process, a PLM or QMS platform, a reorganization that moves product management under a different executive. In the same TechLink study, only 40% of companies reported extensively using a gating process so formal process is a real gap for many.
But a gate only works if the team at the gate is willing to make the call. A PLM system documents the bill of materials; it doesn’t resolve the argument between R&D and product management about whether the kit is ready. That argument is a team behavior, and it needs a team-level fix.
How does High-Performance Science Teams™ work for product teams?
The program applies Guttman Development Strategies’ horizontal high-performance team model to the intact new product introduction team, working on real launches in your pipeline.
| Launch pattern | Root behavior | What HPT installs |
| Spec creep and slipped design freeze | No agreed decision rule for “good enough” | A decision protocol tied to product requirements, with a named decision owner and date |
| PM accountability without authority | Functional goals outrank launch goals | Shared launch goals and cross-functional commitments each function signs |
| Late QC and stability criteria | QC brought in at design transfer | QC, regulatory, and operations seated in the core team from feasibility onward |
| Marketing–R&D claims conflict | Disagreement handled by escalation | A conflict protocol that settles claims against the validation data, in the room |
| Unready tech support and FAS | Commercial handoff treated as an event | Peer accountability for launch readiness across R&D, marketing, and support |
How does this connect to commercial readiness?
High-Performance Science Teams™ aligns the team that builds the product. Bench to Business™, our companion program, builds the customer-facing skills of the Field Application Scientists and technical specialists who support it. Many product companies run both: one for the launch team, one for the people carrying the product to customers.
Who is it for?
VPs of Product Management and R&D, CCOs, product marketing leaders, and QC, QA, and operations heads at life science tools, reagent, antibody, assay kit, and consumables companies — typically in the $10M–$500M revenue range and launching multiple products a year.
How do we get started?
Start with the Science Team 360™, a short, confidential team-level diagnostic that shows exactly where decision rights, alignment, and accountability are breaking down inside your product development team. You get a readout before anyone commits to a full engagement.
Request a Science Team 360™ conversation at bench2business.bio.
Frequently asked questions
Why do life science product launches slip?
Most slips trace to cross-functional behavior rather than technical failure: design specs that never freeze, product managers without authority over other functions, QC and regulatory brought in late, and commercial teams trained after launch.
What is a high-performance product development team?
It is a cross-functional team -R&D, product management, QC, regulatory, operations, marketing, and support, that shares one set of launch goals, has explicit decision rights, resolves conflicts openly, and holds each other accountable for launch readiness.
Does High-Performance Science Teams™ replace a stage-gate process?
No. It makes gates work by ensuring the team at each gate makes a clear decision on agreed criteria instead of deferring it.
Is this relevant for RUO-to-IVD transitions?
Yes. Teams moving toward design-controlled environments benefit from building cross-functional documentation and decision habits early, rather than back-filling them.
How do we start?
With the Science Team 360™, a confidential team diagnostic that shows where alignment, decision rights, and accountability break down in your launch team.
Sources
- TechLink, 2024 R&D Innovation Performance Study — Executive Summary (conducted by The MPI Group; n=152 U.S. executives, cross-industry).
- Guttman, H.M. Great Business Teams: Cracking the Code for Standout Performance (Wiley, 2008) — https://www.guttmandev.com/great-business-teams
Figures from third-party studies are cited as published. Cross-industry data is presented as directional for life science. Program outcomes described are targets teams track against their own Science Team 360™ baseline, not guaranteed results.